Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

CNS Medication Trials

San Antonio, Texas

CNS medication trials in San Antonio, TX

25 CNS medication studies are recruiting participants at sites in San Antonio as of November 17, 2026, according to ClinicalTrials.gov. CNS Medication Trials can help you understand your options and connect with a study team.

Call (888) 927-5768
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

San Antonio at a glance

Depression studies recruiting in San Antonio

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder

    • Phase 3
    • Ages 18 to 85
    • All sexes
    Sponsor
    Cybin IRL Limited
    Study site
    Flourish Research San Antonio
    Registry record
    NCT06793397 · updated
  2. Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

    • Phase 3
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07484217 · updated
  3. Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)

    • Phase 2
    • Ages 18 to 65
    • All sexes
    Sponsor
    Autobahn Therapeutics, Inc.
    Study site
    Autobahn Site #146
    Registry record
    NCT06633016 · updated
  4. A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms

    • Phase 4
    • Ages 18 to 65
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT06223880 · updated

Source: ClinicalTrials.gov. Data processed . See every depression study recruiting in San Antonio, TX on ClinicalTrials.gov.

Schizophrenia studies recruiting in San Antonio

  1. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

    • Phase 3
    • Ages 55 to 90
    • All sexes
    Sponsor
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company
    Study site
    Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases
    Registry record
    NCT06585787 · updated
  2. Comparing Antipsychotic Medications in LBD Over Time

    • Phase 4
    • All ages
    • All sexes
    Sponsor
    The University of Texas Health Science Center at San Antonio
    Study sites
    UT Health Science Center - San Antonio · University Health System
    Registry record
    NCT05590637 · updated

Source: ClinicalTrials.gov. Data processed . See every schizophrenia study recruiting in San Antonio, TX on ClinicalTrials.gov.

ADHD studies recruiting in San Antonio

  1. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)

    • Phase 3
    • Ages 6 to 11
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717879 · updated
  2. Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-3)

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    Axsome Therapeutics, Inc.
    Registry record
    NCT07717892 · updated

Source: ClinicalTrials.gov. Data processed . See every ADHD study recruiting in San Antonio, TX on ClinicalTrials.gov.

Parkinson's disease studies recruiting in San Antonio

  1. A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8001)
    Registry record
    NCT06841354 · updated
  2. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology-San Antonio Medical Center ( Site 8001)
    Registry record
    NCT06952504 · updated
  3. A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8004)
    Registry record
    NCT06966700 · updated
  4. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

    • Phase 3
    • Ages 18 and older
    • Female participants
    Sponsor
    AstraZeneca
    Registry record
    NCT06989112 · updated
  5. An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

    • Phase 2
    • Ages 50 to 80
    • All sexes
    Sponsor
    Yale University
    Study site
    University of Texas Health Science Center- San Antonio
    Registry record
    NCT06996652 · updated
  6. A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Texas Oncology - San Antonio ( Site 8002)
    Registry record
    NCT06312176 · updated
  7. A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT07161414 · updated

Source: ClinicalTrials.gov. Data processed . See every Parkinson's disease study recruiting in San Antonio, TX on ClinicalTrials.gov.

Multiple sclerosis (MS) studies recruiting in San Antonio

  1. A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Lone Star Neurology
    Registry record
    NCT07299019 · updated
  2. A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Zenas BioPharma (USA), LLC
    Study site
    Lone Star Neurology
    Registry record
    NCT07067463 · updated
  3. Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis

    • Phase 3
    • Ages 18 to 60
    • All sexes
    Sponsor
    Sanofi
    Study site
    Neurology Center of San Antonio- Site Number : 8400099
    Registry record
    NCT07325292 · updated

Source: ClinicalTrials.gov. Data processed . See every multiple sclerosis study recruiting in San Antonio, TX on ClinicalTrials.gov.

Epilepsy studies recruiting in San Antonio

  1. A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Xenon Pharmaceuticals Inc.
    Study site
    University of Texas Health Science Center at San Antonio
    Registry record
    NCT05667142 · updated

Source: ClinicalTrials.gov. Data processed . See every epilepsy study recruiting in San Antonio, TX on ClinicalTrials.gov.

Migraine studies recruiting in San Antonio

  1. A Study to Assess the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine

    • Phase 3
    • Ages 18 to 75
    • All sexes
    Sponsor
    TriGemX Bio, Inc.
    Study sites
    Clinical Trials of Texas, LLC, A Flourish Research Site · San Antonio Clinical Trials
    Registry record
    NCT07816367 · updated
  2. A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

    • Phase 3
    • Ages 12 to 17
    • All sexes
    Sponsor
    H. Lundbeck A/S
    Study site
    Road Runner Research (RRR)
    Registry record
    NCT04965675 · updated
  3. Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    Pfizer
    Study site
    DCT-Stone Oak, LLC dba Discovery Clinical Trials
    Registry record
    NCT05156398 · updated
  4. A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    H. Lundbeck A/S
    Study site
    Road Runner Research (RRR)
    Registry record
    NCT05164172 · updated
  5. A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    H. Lundbeck A/S
    Study site
    Road Runner Research (RRR)
    Registry record
    NCT05897320 · updated
  6. Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    • Phase 3
    • Ages 6 to 17
    • All sexes
    Sponsor
    AbbVie
    Study site
    Road Runner Research /ID# 230527
    Registry record
    NCT05125302 · updated

Source: ClinicalTrials.gov. Data processed . See every migraine study recruiting in San Antonio, TX on ClinicalTrials.gov.

Ask about studies near San Antonio

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Texas

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a medication, as each study is coded in the registry.

CNS Medication Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-5768

or send a short form

How should we reach you?

Call